MOXY: Maternal Oxygen Supplementation for Intrauterine Resuscitation

Sponsor
Washington University School of Medicine (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05681624
Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (NIH), University of Michigan (Other), University of Texas at Austin (Other), Women and Infants Hospital of Rhode Island (Other), Dell Children's Medical Center of Central Texas (Other), Brown University (Other)
2,124
2
52

Study Details

Study Description

Brief Summary

More than 80% of the 3 million women who labor and deliver each year in the United States undergo continuous electronic fetal monitoring (EFM) during labor in order to fetal hypoxia and prevent the transition to acidemia, expedited operative delivery, and/or neonatal morbidity. Category II EFM is the most commonly observed group of fetal heart rate features in labor. One common response to Category II EFM is maternal oxygen (O2) supplementation. The theoretic rationale for O2 administration is that it increases O2 transfer to a hypoxic fetus. There are conflicting national guidelines regarding O2 administration - the American College of Obstetricians and Gynecologists suggest O2 is ineffective, whereas the Association of Women's Health, Obstetric, and Neonatal Nurses recommend continued use given lack of definitive data on safety and efficacy. A recent national survey of nearly 600 Labor & Delivery providers in February 2022 revealed that 49% still use O2 . Thus, there remains equipoise on the topic and high-quality data on the safety of intrapartum O2 is needed. None of the trials to date have studied the effect of intrapartum O2 on important clinical measures of neonatal or maternal morbidity. This safety data is imperative because the field of obstetrics must hold supplemental O2 to the same rigorous standards applied to any drug used in pregnancy. Without data on these definitive outcomes, it will be challenging to implement evidence-based recommendations for supplemental O2 use on Labor & Delivery. The investigators will conduct a large, multicenter, randomized noninferiority trial of O2 supplementation versus room air in patients with Category II EFM in labor.

Condition or Disease Intervention/Treatment Phase
  • Other: Maternal oxygen supplementation
  • Other: Room air
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
2124 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Maternal Oxygen Supplementation for Intrauterine Resuscitation: a Multicenter Randomized Trial
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Aug 30, 2026
Anticipated Study Completion Date :
Aug 1, 2027

Arms and Interventions

Arm Intervention/Treatment
Other: Oxygen

Other: Maternal oxygen supplementation
Maternal oxygen supplementation 10 liters/minute via nonrebreather mask

Active Comparator: Room air

Other: Room air
Room air, no mask

Outcome Measures

Primary Outcome Measures

  1. Percentage of neonates meeting criteria for composite neonatal morbidity [28 days of life]

    One of the following diagnoses: Neonatal death, acidemia, meconium aspiration with pulmonary hypertension, hypoglycemia, hypoxic ischemic encephalopathy ,hypothermia treatment, seizure, respiratory distress

Secondary Outcome Measures

  1. Perentage of patients with operative delivery (cesarean or operative vaginal delivery) [At delivery]

  2. Percentage of patients with operative delivery for the indication of nonreassuring fetal status [At delivery]

  3. Percentage of neonates with neonatal death [28 days of life]

  4. Percentage of neonates with acidemia (pH<7.1) [28 days of life]

  5. Percentage of neonates with meconium aspiration with pulmonary hypertension [28 days of life]

  6. Percentage of neonates with hypoglycemia [28 days of life]

  7. Percentage of neonates with hypoxic ischemic encephalopathy [28 days of life]

  8. Percentage of neonates with hypothermia treatment [28 days of life]

  9. Percentage of neonates with seizure [28 days of life]

  10. Percentage of neonates with respiratory distress [28 days of life]

  11. umbilical artery base excess [At delivery]

  12. umbilical artery partial pressure oxygen [At delivery]

  13. umbilical artery partial pressure carbon dioxide [At delivery]

  14. Percentage of patients with composite maternal morbidity [Within 2 weeks of delivery]

    any diagnosis of the following: postpartum hemorrhage [estimated blood loss >1000 mL]; severe perineal laceration, endometritis

  15. Apgars at 5 and 10 minutes [At 5 and 10 minutes of neonatal life]

  16. Apgar<5 at 5 and 10 mins [At 5 and 10 minutes of neonatal life]

  17. Percentage of neonates with Neonatal Intensive care unit admission [28 days of life]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Singleton gestation

  • Gestational age>=37 weeks

  • Spontaneous labor or induction of labor

  • English or spanish speaking

  • Planned continuous fetal monitoring

Exclusion Criteria:
  • Preterm gestation

  • Major fetal anomaly

  • Multiple gestation

  • Category III fetal monitoring at time of admission

  • Maternal hypoxia <95%

  • Planned or scheduled cesarean delivery

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Washington University School of Medicine
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • University of Michigan
  • University of Texas at Austin
  • Women and Infants Hospital of Rhode Island
  • Dell Children's Medical Center of Central Texas
  • Brown University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT05681624
Other Study ID Numbers:
  • 202209042
  • R01HD108614
First Posted:
Jan 12, 2023
Last Update Posted:
Jan 31, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 31, 2023